telmisartan can modulate the ERK1/2, TAK1 and NF-κB signaling axis, such as agonist of PPARγ, exerting antitumor effects, and increasing tumor sensitivity to sorafenib [110]. This evidence concerns the gene PPARG and neoplasm.